Cargando…

Development of a Model Care Pathway for Myasthenia Gravis

Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations....

Descripción completa

Detalles Bibliográficos
Autores principales: Payedimarri, Anil babu, Ratti, Matteo, Rescinito, Riccardo, Vasile, Alessandra, Seys, Deborah, Dumas, Hervé, Vanhaecht, Kris, Panella, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582978/
https://www.ncbi.nlm.nih.gov/pubmed/34770107
http://dx.doi.org/10.3390/ijerph182111591
_version_ 1784597110478340096
author Payedimarri, Anil babu
Ratti, Matteo
Rescinito, Riccardo
Vasile, Alessandra
Seys, Deborah
Dumas, Hervé
Vanhaecht, Kris
Panella, Massimiliano
author_facet Payedimarri, Anil babu
Ratti, Matteo
Rescinito, Riccardo
Vasile, Alessandra
Seys, Deborah
Dumas, Hervé
Vanhaecht, Kris
Panella, Massimiliano
author_sort Payedimarri, Anil babu
collection PubMed
description Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice.
format Online
Article
Text
id pubmed-8582978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85829782021-11-12 Development of a Model Care Pathway for Myasthenia Gravis Payedimarri, Anil babu Ratti, Matteo Rescinito, Riccardo Vasile, Alessandra Seys, Deborah Dumas, Hervé Vanhaecht, Kris Panella, Massimiliano Int J Environ Res Public Health Article Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice. MDPI 2021-11-04 /pmc/articles/PMC8582978/ /pubmed/34770107 http://dx.doi.org/10.3390/ijerph182111591 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Payedimarri, Anil babu
Ratti, Matteo
Rescinito, Riccardo
Vasile, Alessandra
Seys, Deborah
Dumas, Hervé
Vanhaecht, Kris
Panella, Massimiliano
Development of a Model Care Pathway for Myasthenia Gravis
title Development of a Model Care Pathway for Myasthenia Gravis
title_full Development of a Model Care Pathway for Myasthenia Gravis
title_fullStr Development of a Model Care Pathway for Myasthenia Gravis
title_full_unstemmed Development of a Model Care Pathway for Myasthenia Gravis
title_short Development of a Model Care Pathway for Myasthenia Gravis
title_sort development of a model care pathway for myasthenia gravis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582978/
https://www.ncbi.nlm.nih.gov/pubmed/34770107
http://dx.doi.org/10.3390/ijerph182111591
work_keys_str_mv AT payedimarrianilbabu developmentofamodelcarepathwayformyastheniagravis
AT rattimatteo developmentofamodelcarepathwayformyastheniagravis
AT rescinitoriccardo developmentofamodelcarepathwayformyastheniagravis
AT vasilealessandra developmentofamodelcarepathwayformyastheniagravis
AT seysdeborah developmentofamodelcarepathwayformyastheniagravis
AT dumasherve developmentofamodelcarepathwayformyastheniagravis
AT vanhaechtkris developmentofamodelcarepathwayformyastheniagravis
AT panellamassimiliano developmentofamodelcarepathwayformyastheniagravis